Search Results - "van den Eertwegh, A.J"

(Neo)adjuvant systemic therapy for melanoma by van Zeijl, M.C.T, van den Eertwegh, A.J, Haanen, J.B, Wouters, M.W.J.M

“…Abstract Surgery still is the cornerstone of treatment for patients with stage II and III melanoma, but despite great efforts to gain or preserve locoregional…”
Get full text

A Flexible Multi-State Modelling Framework for the Simulation of Cancer Progression and Cancer Care by van der Meijde, E, van den Eertwegh, A.J, Uyl - de Groot, C.A, Coupe, V.M.H

Get full text

Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model Framework by Van der Meijde, E, van den Eertwegh, A.J, Fijneman, R.J, Meijer, G.A, Linn, S.C, Coupe, V.M

Get full text

PRM110 - Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model Framework by Van der Meijde, E., van den Eertwegh, A.J., Fijneman, R.J., Meijer, G.A., Linn, S.C., Coupe, V.M.

Get full text

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression by van Houdt, Inge S., Sluijter, Berbel J.R., Moesbergen, Laura M., Vos, Wim M., de Gruijl, Tanja D., Molenkamp, Barbara G., van den Eertwegh, Alfons J.M., Hooijberg, Erik, van Leeuwen, Paul A.M., Meijer, Chris J.L.M., Oudejans, Joost J.

“…In this study we investigated whether the presence of specific populations of tumor infiltrating lymphocytes (TILs) in diagnostic primary melanoma biopsies are…”
Get full text

PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS by Leeneman, B., Franken, M., Aarts, M.J., van Akkooi, A.C., van den Berkmortel, F.W., van den Eertwegh, A.J., de Groot, J.W., Herbschleb, K.H., van der Hoeven, K.J., Hospers, G.A., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P., ten Tije, A.J., van der Veldt, A.A., Vreugdenhil, G., Wouters, M.W., van Zeijl, M.C., Haanen, J.B., Uyl-de Groot, C.A.

Get full text

763PDUPDATED OVERALL SURVIVAL (OS) FROM THE PHASE 3 TRIAL, CA184-043: IPILIMUMAB (IPI) VS PLACEBO (PBO) IN PATIENTS WITH POST-DOCETAXEL METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) by Fizazi, K., Drake, C.G., Kwon, E.D., Bossi, A., van den Eertwegh, A.J., Scher, H.I., Beer, T.M., McHenry, M.B., Liu, D., Gerritsen, W.R., Logothetis, C.

“…Abstract Aim: Ipi is a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4) to augment antitumor immune responses. The phase 3…”
Get full text

Updated Overall Survival (Os) from the Phase 3 Trial, Ca184-043: Ipilimumab (Ipi) Vs Placebo (Pbo) in Patients with Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (Mcrpc) by Fizazi, K., Drake, C.G., Kwon, E.D., Bossi, A., van den Eertwegh, A.J., Scher, H.I., Beer, T.M., McHenry, M.B., Liu, D., Gerritsen, W.R., Logothetis, C.

Get full text

Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population by van Zeijl, M.C.T., Wouters, M.W.J.M., van den Eertwegh, A.J., Aarts, M.J., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Franken, M.G., de Groot, J.W.B., Herbschleb, K.H., van der Hoeven, J.J.M., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., Ten Tije, A.J., Van der Veldt, A.A.M., Vreugdenhil, G., Haanen, J.B.A.G.

Get full text

PRM232 - A Flexible Multi-State Modelling Framework for the Simulation of Cancer Progression and Cancer Care by van der Meijde, E., van den Eertwegh, A.J., Uyl - de Groot, C.A., Coupe, V.M.H.

Get full text